Levetiracetam A.Forall (Levetiracetam)

Levetiracetam exerts its effect by binding to the synaptic vesicle protein SV2A, which plays a key role in the regulation of neurotransmitter release. This binding modulates vesicle exocytosis, leading to decreased neuronal excitability and a reduction in the spread of epileptic discharges throughout the central nervous system.

The dosage of Levetiracetam A.Forall is individualized and determined by the prescribing healthcare professional based on the patient’s clinical condition, age, renal function and response to therapy. No fixed regimen is provided here; the prescriber will set the appropriate dose and infusion rate.

Levetiracetam is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy only if the potential benefit outweighs any possible risk. Limited data are available for breastfeeding, so a risk‑benefit assessment should be performed by the clinician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Levetiracetam A.Forall. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After receiving the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

Compared with older antiepileptics such as carbamazepine or valproic acid, levetiracetam has a relatively favourable drug‑interaction profile and does not require routine therapeutic drug monitoring. It is also available in an intravenous formulation for rapid seizure control. However, individual response varies, and clinicians consider efficacy, tolerability, comorbidities and potential interactions when selecting therapy.

Levetiracetam A.Forall should be stored at ambient temperature, below 25 °C, protected from light, moisture and excessive heat. Keep the vials in their original packaging until use and avoid freezing. Inspect the solution for particulate matter or discoloration before administration.

Levetiracetam A.Forall is administered intravenously. The solution is typically infused over a period determined by the prescribing physician, often as a slow infusion to minimise infusion‑related reactions. Administration should be performed by qualified healthcare personnel in a setting equipped for intravenous therapy.

Serious adverse reactions include severe allergic responses such as rash, angio‑edema or anaphylaxis; significant mood alterations including depression, suicidal ideation or severe anxiety; hematologic abnormalities like leukopenia or thrombocytopenia; and hepatic dysfunction manifested by elevated liver enzymes or jaundice. Prompt medical evaluation is required if any of these events occur.

Levetiracetam A.Forall is contraindicated in patients with a known hypersensitivity to levetiracetam or any of the formulation excipients. Caution is advised in individuals with severe renal impairment, active psychiatric disorders, or a history of severe allergic reactions to other antiepileptic drugs. The decision to use the product should be made by a qualified clinician.